

From: [Morgan, Mickey D. \(CMS/CMCS\)](#)
To: [Nancy Nesser](#)
Cc: [Kerri Wade](#); [Tywanda Cox](#); [Coster, John M. \(CMS/CMCS\)](#); [Shuman, Stacey S. \(CMS/CMCHO\)](#)
Subject: Oklahoma SRA
Date: Tuesday, June 27, 2017 2:07:38 PM

Dear Nancy,

We have reviewed the Oklahoma Supplemental Rebate Agreement (SRA) in which the Sovereign States Drug Consortium (SSDC) was added. In addition, SSDC is granted permission to negotiate supplemental rebate(s) on behalf of the state of Oklahoma. With the SRA's inclusion in OK16-0030 (Covered Outpatient Drug Rule) State Plan Amendment (SPA), the State is not required to submit a separate SPA. As requested by the State, we are pleased to inform you that the SRA is authorized for use effective January 1, 2017.

We believe that the Oklahoma SRA continues to be consistent with the objectives of the Medicaid program. Please note that this approval extends only to the revised SRA, amendments referenced in this email. If changes are subsequently made to the supplemental drug rebate agreements, amendments or exhibits, any such documents should be submitted to CMS for review and authorization.

By copy of this email, the Dallas Region Office is also notified of this SRA revision. If you should have any further questions or require additional information, please contact Mickey Morgan at mickey.morgan@cms.hhs.gov.

Thank you,

Mickey Morgan | Policy Analyst | Pharmacy Division |
Disabled and Elderly Health Programs Group | Center for Medicaid and CHIP Services
Centers for Medicare & Medicaid Services (CMS) | 7500 Security Blvd.
Baltimore, MD 21244-1850 | Telephone Number: 410-786-4048
Fax Number: 410-786-6730 (call to confirm pick-up)
Email: mickey.morgan@cms.hhs.gov

The decision in this response is limited to and based upon the facts described in this email and any attachments provided and our understanding of the facts as described in the emails and attachments submitted. If a subsequent review by CMS, by the Office of Inspector General, or another authorized government agency determines or reveals that additional adjustments or revisions are necessary, the manufacturer is responsible for complying with that determination. This response cannot be considered an advisory opinion under section 1128D(b) of the Social Security Act, since only the Inspector General of the U.S. Department of Health and Human Services has been authorized to issue advisory opinions relating to health care fraud and abuse under that section. This response should not be interpreted as acquiescence by the Government to the arrangements described herein. Further, this response is not a release of any liability.

NOTICE: This e-mail and any attachments to it may contain information that is PRIVILEGED and CONFIDENTIAL under state and federal law and is intended only for the use of the specific individual(s) to whom it is addressed. This information may only be used or disclosed in accordance with law, and you may be subject to penalties under law for improper use or further disclosure of the information in this e-mail and its attachments. If you have received this e-mail in error, please immediately notify the person named above by reply e-mail, and then delete the one you received

